The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Ławicki, Sławomir ^a   Bȩdkowska, Grazyna Ewa ^a   Gacuta Szumarska, Ewa ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

CA125; HE4; Ovarian Cancer; Tumor Markers; VEGF

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENDOMETRIOID CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84879823068     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-45     Document Type: Article

References (61)

1. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Siegel R, Ward E, Brawley O, Jemal A, CA Cancer J Clin 2011 61 212 236 10.3322/caac.20121 21685461
2. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
3. The biology of ovarian cancer: new opportunities for translation. Bast RC Jr, Hennessy B, Mills GB, Nat Rev Cancer 2009 9 415 442 10.1038/nrc2644 19461667
4. Effect of BRCA1/2 mutations on long term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S, J Clin Oncol 2008 26 20 25 10.1200/JCO.2007.11.6905 18165636
5. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilwestro P, Granai CO, Bast RC, Gynecol Oncol 2008 108 402 408 10.1016/j.ygyno.2007.10.017 18061248 (Pubitemid 351174295)
6. Ovarian cancer: biomarker proteomic diagnosis in progress. Zhang Y, Guo B, Bi R, Appl Biochem Biotechnol 2012 168 910 916 10.1007/s12010-012-9829-y 22945560
7. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR, Biomed Pharmacother 2004 58 24 38 10.1016/j.biopha.2003.11.003 14739059 (Pubitemid 38117046)
8. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. Haaften-Day C, Yu S, Fengji X, Yinhua Y, Berchuck A, Havrilesky LJ, de Bruijn HWA, van der Zee GJ, Bast RC Jr, Hacker NF, Cancer 2001 92 2837 2844 10.1002/1097-0142(20011201)92:11<2837::AID- CNCR10093>3.0.CO;2-5 11753957 (Pubitemid 33091920)
9. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4 and CA 125. Shah SA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW, Cancer Epidemiol Biomarkers Prev 2009 18 1365 1372 10.1158/1055-9965.EPI-08-1034 19423517
10. Use of a symptom index, CA 125, and HE-4 to predict ovarian cancer. Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, Paley P, Urban N, Gynecol Oncol 2010 116 378 383 10.1016/j.ygyno.2009.10.087 19945742
11. The plasma levels and diagnostic utility of granulocyte-colony stimulating factor (G-CSF) and macrophage-colony stimulating factor (M-CSF) in ovarian cancer patients. Ławicki S, Czygier M, Gacuta-Szumarska E, Knapp P, Szmitkowski M, Pol Merkur Lek 2006 21 465 468 (Pubitemid 44875504)
12. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA 125 II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. Skates S, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC, J Clin Oncol 2005 22 4059 4066 (Pubitemid 41185174)
13. The plasma levels and diagnostics utility of granulocyte-colony stimulating factor (G-CSF) and macrophage-colony stimulating factor (M-CSF) in ovarian cancer patients. Ławicki S, Czygier M, Gacuta-Szumarska E, Knapp P, Szmitkowski M, Pol Merkur Lek 2006 125 465 468 (Pubitemid 44875504)
14. The role of interleukin-6 in gynaecological malignancies. Jermaine IG, Coward, Hagen Kulbe, Cytokine Growth Factor Rev 2012 23 333 342 10.1016/j.cytogfr.2012.08.005 23031497
15. Evaluation of ovarian cancer remission markers HE4, MMP7 and mesothelin by comparison to the established marker CA125. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, Hellsttom KE, Urban N, Gynecol Oncol 2012 125 65 69 10.1016/j.ygyno.2011.11.050 22155417
16. Relationship between the expression of VEGF signal components and matrix metalloproteinases in ovarian tumors. Gersthein ES, Kushlinsky DN, Levkina NV, Tereshkina IV, Nosov VB, Laktionov KP, Adamyan LV, Bull Exp Biol Med 2011 151 431 435
17. Clinical significance of serum tumor markers measurements in patients with ovarian cancer. Kamińska J, Kowalska M, Voice 2008 2 16 21
18. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Folkman J, Nat Med 1995 1 27 31 10.1038/nm0195-27 7584949
19. VEGF as a key mediator of angiogenesis in cancer. Carmeliet P, Oncology 2005 69 Suppl 3 4 10 16301830 (Pubitemid 41680947)
20. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vinent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D, Nature 2005 438 820 827 10.1038/nature04186 16341007 (Pubitemid 41753060)
21. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M, Cell 2010 140 268 279 10.1016/j.cell.2009. 12.046 20141840
22. Lymphatic vessels and lymphagiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Schoppmann SF, Horvat R, Birner P, Oncol Rep 2002 9 455 460 11956609
23. Vascular endothelial growth factor in the serum of breast cancer patients. Berezov TT, Ovchinnikova LK, Kuznetsova OM, Karabekova ZK, Vorotnikov IK, Tuleuova AA, Katunina AI, Dvorova EK, Bull Exp Biol Med 2009 148 419 424 10.1007/s10517-010-0727-4 20396703
24. Serum levels of VEGF and VEGF-C in patients with endometrial cancer. Dobrzycka B, Terlikowski SJ, Kowalczuk O, Kulikowski M, Niklinski J, Eur Cytokine Netw 2011 22 45 51 21411409
25. Analysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics. Piastowska-Ciesielska AW, Płuciennik E, Wójcik-Krowiranda K, Bieńkiewicz A, Bednarek A, Ochȩdalski T, Tumour Biol 2012 33 767 774 10.1007/s13277-011-0292-0 22170435
26. Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer. Mazurek A, Pierzynski P, Kuc P, Kopinski P, Terlikowski S, Niklińska W, Trojan J, Laudański T, Neoplasma 2004 51 193 197 15254672 (Pubitemid 38821498)
27. Properative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller A, Gynecol Oncol 2006 103 512 517 10.1016/j.ygyno.2006.03.058 16750560 (Pubitemid 44740099)
28. Comparison of VEGF, IL-8 and beta-FGF concentrations in the serum and ascites of patients with ovarian cancer. Sadłecki P, Walentowicz- Sadłecka M, Szymański W, Grabiec M, Ginekol Pol 2011 82 498 502 21913426
29. Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Carrillo-de Santa Pau E, Carrillo Arias F, Caso Pelaez E, Muguruza Trueba I, Sanchez Hernandez I, Munoz Molina GM, Moreno Balsalobre R, Sacristan Lopez S, Gomez-Pinillos A, Toledo Lobo Mdel V, Cancer Invest 2010 28 393 398 19968501
30. Toward standardized high-through serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. Bunger S, Haug U, Kelly FM, Klempt-Giessing K, Cartwright A, Posorski N, Dibbelt L, Fitzgerald SP, Bruch HP, Roblick UJ, von Eggeling F, Brenner H, Habermann JK, J Biomol Screen 2011 16 1018 1026 10.1177/1087057111414894 21807963
31. Preliminary results regarding vascular endothelial growth factor (VEGF-A) levels in the serum of gastric cancer patients. Halmaciu I, Gurzu S, Dobreanu M, Suciu BA, Brinzaniuc K, Rev Med Chir Soc Med Nat Iasi 2012 116 446 451 23077935
32. Clinical practice. Screening for ovarian cancer. Clarke-Pearson DL, N Engl J Med 2009 361 170 177 10.1056/NEJMcp0901926 19587342
33. The CA 125 tumour-associated antigen: a review of the literature. Jacobs I, Bast RC Jr, Hum Reprod 1989 4 1 12 10.1093/humrep/4.suppl-1.1 2533216 (Pubitemid 19069900)
34. HE4 as a biomarker for ovarian and endometrial cancer management. Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW, Expert Rev Mol Diagn 2009 9 555 566 10.1586/erm.09.39 19732003
35. Ovarian cancer-diagnostical and therapeutical dilema in oncological gynecology. Urban A, Miszczyk L, Wspol Onkol 2003 7 294 300
36. Development of a multimarker assay for early detection of ovarian cancer. Yurkowetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE, J Clin Oncol 2010 28 2159 2166 10.1200/JCO.2008.19.2484 20368574
37. Diagnostic performances of HE4 and CA 125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Park Y, Lee J-H, Hong DJ, Lee EY, Kim H-S, Clin Biochem 2011 44 884 888 10.1016/j.clinbiochem.2011.04.011 21549107
38. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Ruggeri G, Bandiera E, Zanotti L, Belloni S, Ravaggi A, Romani C, Bignotti E, Tassi RA, Tognon G, Galli C, Caimi L, Pecorelli S, Clin Chim Acta 2011 412 1447 1453 10.1016/j.cca.2011.04.028 21557935
39. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Li L, Wang L, Zhang W, Tang B, Zhang J, Song H, Yao D, Tang Y, Chen X, Yang Z, Wang G, Li X, Zhao J, Ding H, Reed D, Li Q, Anticancer Res 2004 24 1973 1979 15274387 (Pubitemid 38954620)
40. Vascular endothelial growth factor in ovarian cancer patients. Sledakova I, Tosner J, Kopecky O, Vroblova V, Rezac A, Skapinec P, Andrys C, Ceska Gynekol 2012 77 415 420 23116346
41. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. Ivoino F, Ferraraccio F, Orditura M, Antoniol G, Morgillo F, Cascone T, Diadema MR, Aurilio G, Santabarbara G, Ruggiero R, Belli C, Irlandese E, Fasano M, Ciardiello F, Procaccini E, Lo Schiavo F, Catalano G, De Vita F, Cancer Invest 2008 26 250 255 10.1080/07357900701560612 18317965 (Pubitemid 351329002)
42. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. Cheng D, Liang B, Li Y, PLoS One 2013 8 55309 10.1371/journal.pone.0055309 23383322
43. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Candido dos Reis FJ, Moreira de Andrade J, Bighetti S, Gynecol Obstet Invest 2002 54 132 136 10.1159/000067877 12571433 (Pubitemid 36184420)
44. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Molina R, Escudero JM, Auge JM, Filella X, Foj L, Torne A, Lejarceguli J, Pahisa J, Tumor Biol 2011 32 1087 1095 10.1007/s13277-011-0204-3
45. Significance of HE4 estimation in comparison with CA 125 in diagnosis of ovarian cancer and assessment of treatment response. Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM, Diagn Pathol 2013 8 11 10.1186/1746-1596-8-11
46. An ovarian cancer malignancy risk index composed of HE4, CA 125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Macuks R, Baidekalna I, Donina S, Tumor Biol 2012 33 1811 1817 10.1007/s13277-012-0440-1
47. Comparison of HE4, Ca 125 and ROMA algorithm in women with a pelvic mass: correlation with pathological out come. Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M, Gynecol Oncol 2013 128 233 238 10.1016/j.ygyno.2012.11.026 23200911
48. The assessment of angiogenic factors VEGF, VEGER-2 and VCAM-1 in the serum of women with malignant ovarian tumours before and after the menopause. Czekierdowski A, Czekierdowska S, Przegla̧d Menopauzalny 2007 3 128 133 23828419 (Pubitemid 47161964)
49. Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Mattern J, Stammler G, Koomagi R, Wallwiener D, Kaufmann M, Volm M, Anticancer Res 1997 17 621 624 9066589 (Pubitemid 27105537)
50. Ovarian cancer metastasis: integrating insights from disparate model organisms. Naora H, Montell DJ, Nat Rev Cancer 2005 5 355 366 15864277 (Pubitemid 40637827)
51. Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients. Ławicki S, Gacuta-Szumarska E, Bȩdkowska GE, Szmitkowski M, Growth Factors 2012 30 357 366 10.3109/08977194.2012.724407 22988839
52. Serum HE4 levels are less frequently elevated than CA 125 in women with benign gynecologic disorders. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC Jr, Am J Obstet Gynecol 2012 206 351.e1-8 22284961
53. Correlartion of preoperative serum vascular endothelial growth factor level with CA 125 level in patients with epithelial ovarian cancer and its prognostic value. Tan XJ, Lang JH, Shen K, Wang L, Wu M, Xu XY, Zhonghua Fu Chan Ke Za Zhi 2008 43 9 12 18366924
54. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. Mahner S, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosh K, Mueller V, BMC Cancer 2010 10 139 149 10.1186/1471-2407-10-139 20388222
55. Evaluation of HE4 as an extrabiomarker to CA 125 to improve detection of ovarian carcinoma: is it time for a step forward? Azzam AZ, Hashad DI, Kamel NA, Arch Gynecol Obstet 2013 Jan 30 [Epub ahead of print] 9921991
56. Hematopoietic cytokines as tumor markers in gynecological malignancies: A multivariate analysis with ROC curve in endometrial cancer patients. Ławicki S, Bȩdkowska GE, Gacuta-Szumarska E, Szmitkowski M, Growth Factors 2012 30 29 36 10.3109/08977194.2011.627332 22010785
57. Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients. Ławicki S, Bȩdkowska GE, Gacuta-Szumarska E, Knapp P, Szmitkowski M, Folia Histochem Cytobiol 2012 50 213 219 22763962
58. Vascular endothelial growth factor (VEGF)-a valuable serum tumour marker in patients with colorectal cancer? Broll R, Erdmann H, Duchrow M, Oevermann E, Schwandner O, Market U, Bruch HP, Windhovel U, Eur J Surg Oncol 2001 27 37 42 10.1053/ejso.2000.1052 11237490 (Pubitemid 32229693)
59. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Chan KKL, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW, Gynecol Oncol 2013 128 239 244 10.1016/j.ygyno.2012.09.034 23063998
60. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Holcomb K, Vucetic Z, Miller MC, Knapp RC, Am J Obstet Gynecol 2011 205 358.e1-6 21722869
61. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease. Zheng H, Gao Y, Int J Gynecol Cancer 2012 22 1000 1005 10.1097/IGC.0b013e318249bee7 22426406.